drugset / Trial / NCT05453825
A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a study of navicixizumab monotherapy or in combination with paclitaxel or irinotecan in patients with advanced cancer. Patients will be enrolled into one of the following cancer cohorts: * Cohort A: CRC * Cohort B: Gastric and GEJ cancer * Cohort C: TNBC * Cohort D: Platinum-resistant/refractory epithelial ovarian, primary peritoneal, or fallopian tube cancer (ovarian cancer)
Timeline
- Start
- 2022-08-05
- Primary completion
- 2024-04-15
- Completion
- 2024-12-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Irinotecan | Small molecule | 180 mg/m2 | — |
| Subject | Paclitaxel | Small molecule | 80 mg/m2 | — |
| Subject | navicixizumab | Monoclonal antibody | 3 mg/kg | — |